CONCLUSION

Sustained action for scaling up treatment for the HIV epidemic presumes solutions to numerous scientific and management challenges. At the same time, as wealthy, middle-income, and poor nations join together to tackle the overarching challenge of bringing the pandemic under control, it bears emphasizing that the global problem of HIV/AIDS will likely be present for decades despite research findings and optimized interventions. In a few years, when it may be hoped that the initial objectives of WHO’s 3-by-5 campaign and the U.S. Emergency Plan will have been met, we must not abandon the millions started on therapy or ignore the pleas of the tens of millions more who will soon need these medicines. Even short-term interruptions in support could be clinically disastrous and ethically unconscionable by allowing successfully suppressed HIV infections to emerge in drug-resistant forms. Thus, ART must not be seen simply as a short-term goal or the end point of a 5-year plan. The world is indeed at the beginning of a very long path forward that will require vigilant and sustained support.

REFERENCES

Deeks SG, Barbour JD, Martin JN, Swanson MS, Grant RM. 2000. Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection . Journal of Infectious Diseases 181:946–953.


Galvao J. 2002. Access to antiretroviral drugs in Brazil. Lancet 360(9348):1862–1865.

Gray R, Wawer MJ, Brookmeyer R, Sewan Kambo NK, Serwadda D, Wabwire-Mangen F, Lutalo T, Li X, VanCott T, Quinn TC, Rakai Project Team. 2001. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1 discordant couples in Rakai, Uganda. Lancet 357:1149–1153.


John GC, Nduati RW, Mbori-Ngacha DA, Richardson BA, Panteleeff D, Mwatha A, Overbaugh J, Bwayo J, Ndinya-Achola JO, Kreiss JK. 2001. Correlates of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission: Association with maternal plasma HIV-1 RNA load, genital HIV-1 DNA shedding, and breast infections. Journal of Infectious Diseases 183:206–212.


Laniece I, Ciss M, Desclaux A, Diop K, Mbodj F, Ndiaye B, Sylla O, Delaporte E, Ndoye I. 2003. Adherence to HAART and its principle determinants in a cohort of Senegalese adults. AIDS 17:S103–S108.

Nierengarten MB. 2003. Haiti’s HIV equity initiative, Lancet 3:266.


Ometto L, Zanchetta M, Mainardi M, DeSalvo GL, Garcia-Rodriguez MC, Chieco-Bianchi L, Gray L, Newell ML, DeRossi A. 2000. Co-receptor usage of HIV-1 primary isolates, viral burden, and CCR5 genotype in mother-to-child HIV-1 transmission. AIDS 14: 1721–1729.

Orrell C, Bangsberg DR, Badri M, Wood R. 2003. Adherence is not a barrier to successful antiretroviral therapy in South Africa. AIDS 17:1369–1375.


Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, Meehan MO, Lutalo T, Gray RH. 2000. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. New England Journal of Medicine 342:921–929.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement